Iterum Therapeutics PLC
ITRM
查看详细走势图
0.370USD
-0.011-2.86%
收盘 12/19, 16:00（美东）报价延迟15分钟
18.13M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-2.86%
5天
-17.78%
1月
0.00%
6月
-62.63%
今年开始到现在
-79.10%
1年
-79.10%
查看详细走势图
TradingKey Iterum Therapeutics PLC股票评分
单位: USD 更新时间: 2025-12-19操作建议
Iterum Therapeutics PLC当前公司基本面数据相对健康，增长潜力较大。当前估值合理，在生物技术与医疗研究行业排名164/404位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价5.50。中期看，股价处于下降通道。近一个月，市场表现一般，基本面和技术面综合得分也较低。目前股价在压力位和支撑位之间，可以做区间波段操作。
Iterum Therapeutics PLC评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
2
位分析师
买入
评级
5.500
目标均价
+1127.13%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Iterum Therapeutics PLC亮点
亮点风险
Iterum Therapeutics plc is a clinical-stage pharmaceutical company. The Company develops differentiated anti-infectives. It offers ORLYNVAH (sulopenem in an oral tablet formulation) medicine, which is an oral penem antibiotic for the treatment of uncomplicated urinary tract infections caused by the designated microorganisms Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis in adult women. Sulopenem is a potent, thiopenem antibiotic delivered intravenously which is active against bacteria that belong to the group of organisms known as gram-negatives and cause urinary tract and intra-abdominal infections. The Company operates as a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.
Iterum Therapeutics PLC新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Iterum Therapeutics PLC简介
Iterum Therapeutics plc is a clinical-stage pharmaceutical company. The Company develops differentiated anti-infectives. It offers ORLYNVAH (sulopenem in an oral tablet formulation) medicine, which is an oral penem antibiotic for the treatment of uncomplicated urinary tract infections caused by the designated microorganisms Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis in adult women. Sulopenem is a potent, thiopenem antibiotic delivered intravenously which is active against bacteria that belong to the group of organisms known as gram-negatives and cause urinary tract and intra-abdominal infections. The Company operates as a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.
公司代码ITRM
公司Iterum Therapeutics PLC
CEOFishman (Corey N)
网址https://www.iterumtx.com/
常见问题
Iterum Therapeutics PLC(ITRM)的当前股价是多少？
Iterum Therapeutics PLC(ITRM)的当前股价是 0.370。
Iterum Therapeutics PLC的股票代码是什么？
Iterum Therapeutics PLC的股票代码是ITRM。
Iterum Therapeutics PLC股票的52周最高点是多少？
Iterum Therapeutics PLC股票的52周最高点是2.100。
Iterum Therapeutics PLC股票的52周最低点是多少？
Iterum Therapeutics PLC股票的52周最低点是0.362。
Iterum Therapeutics PLC的市值是多少？
Iterum Therapeutics PLC的市值是18.13M。
Iterum Therapeutics PLC的净利润是多少？
Iterum Therapeutics PLC的净利润为-24.77M。
现在Iterum Therapeutics PLC(ITRM)的股票是买入、持有还是卖出？
根据分析师评级，Iterum Therapeutics PLC(ITRM)的总体评级为买入，目标价格为5.500。
Iterum Therapeutics PLC(ITRM)股票的每股收益（EPS TTM）是多少
Iterum Therapeutics PLC(ITRM)股票的每股收益（EPS TTM）是-0.719。
相关品种
